Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial

The proteasome inhibitor bortezomib enhances the effect of the selective estrogen receptor (ER) downregulator (SERD) fulvestrant by causing accumulation of cytoplasmic ER aggregates in preclinical models. The purpose of this trial was to determine whether bortezomib enhanced the effectiveness of ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Adelson, Kerin, Ramaswamy, Bhuvaneswari, Sparano, Joseph A, Christos, Paul J, Wright, John J, Raptis, George, Han, Gang, Villalona-Calero, Miguel, Ma, Cynthia X, Hershman, Dawn, Baar, Joseph, Klein, Paula, Cigler, Tessa, Budd, G Thomas, Novik, Yelena, Tan, Antoinette R, Tannenbaum, Susan, Goel, Anupama, Levine, Ellis, Shapiro, Charles L, Andreopoulou, Eleni, Naughton, Michael, Kalinsky, Kevin, Waxman, Sam, Germain, Doris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515340/
https://www.ncbi.nlm.nih.gov/pubmed/28721390
http://dx.doi.org/10.1038/npjbcancer.2016.37

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515340/
https://www.ncbi.nlm.nih.gov/pubmed/28721390
http://dx.doi.org/10.1038/npjbcancer.2016.37

Ejemplares similares